Related Experiment Videos
Salbutamol or mist in acute bronchiolitis
Insights
Nebulized salbutamol effectively reduced respiratory scores in infants with acute bronchiolitis, showing it is a safe and beneficial treatment option. This study provides evidence for bronchodilator use in managing this common pediatric respiratory illness.
Area of Science:
- Pediatric Pulmonology
- Clinical Trials
- Pharmacology
Background:
- The efficacy of bronchodilators in treating bronchiolitis, a common infant respiratory infection, is debated.
- Current treatment guidelines often do not recommend bronchodilators for bronchiolitis.
- This study addresses the controversy by evaluating a specific bronchodilator, salbutamol.
Purpose of the Study:
- To evaluate the clinical response to nebulized salbutamol in infants diagnosed with acute bronchiolitis.
- To compare the effectiveness of salbutamol against placebo (saline) and supportive care (mist tent).
- To assess the safety and impact of salbutamol on respiratory parameters.
Main Methods:
- A double-blind, placebo-controlled trial involving 156 infants (7 weeks to 24 months) with bronchiolitis.
- Participants were randomized into three groups: nebulized salbutamol, nebulized saline, or mist tent.
- Respiratory scores, heart rate, oxygen saturation, and other clinical signs were monitored before and after treatment.
Main Results:
- The salbutamol group showed a significantly greater decrease in respiratory scores compared to saline and mist tent groups.
- Heart rate remained similar across all groups.
- A non-statistically significant decrease in oxygen saturation was observed in the salbutamol group.
Conclusions:
- Nebulized salbutamol demonstrated effectiveness in improving clinical symptoms of acute bronchiolitis.
- The study supports the safety of salbutamol for treating acute bronchiolitis in infants.
- Findings suggest a potential role for bronchodilators in managing bronchiolitis, challenging current controversies.
Background:
The role of bronchodilators in the treatment of bronchiolitis remains controversial.
Methods:
A double-blind, placebo controlled trial was performed to evaluate the clinical response to nebulized salbutamol. One hundred and fifty-six infants aged between 7 weeks and 24 months who had had an episode of wheezing and other signs and symptoms of bronchiolitis were randomized to three groups as follows: (i) nebulized salbutamol was administered to 52 patients in group I at a dose of 0.15 mg/kg in 2 mL saline; (ii) saline was nebulized to 52 patients in group II and (iii) in group III 52 patients received mist in a tent. All three groups were administered oxygen during the procedures. Treatment was repeated with the same agent after 30 min if the respiratory score was 5 or more. Respiratory rate, heart rate, oxygen saturation and presence of cyanosis, wheezing, retractions were recorded before and after each treatment.
Results:
The decrease in the respiratory score was 5.2 +/- 1.8, 0.82 +/- 2.4 and 1.7 +/- 1.3 in group I, II and III, respectively. The decrease in group I was significantly higher than in the other groups. Heart rate was similar between groups. Oxygen saturation decreased in group I without reaching statistical significance.
Conclusions:
Salbutamol was shown to be effective and safe in the treatment of acute bronchiolitis.